Maia Wealth LLC Buys 1,872 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Maia Wealth LLC boosted its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,639 shares of the medical research company's stock after purchasing an additional 1,872 shares during the quarter. Maia Wealth LLC's holdings in IQVIA were worth $3,030,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Cantillon Capital Management LLC lifted its holdings in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock worth $406,018,000 after purchasing an additional 226,017 shares in the last quarter. Middleton & Co. Inc. MA lifted its stake in shares of IQVIA by 1.3% in the fourth quarter. Middleton & Co. Inc. MA now owns 48,438 shares of the medical research company's stock valued at $9,519,000 after buying an additional 601 shares in the last quarter. Nichols & Pratt Advisers LLP MA grew its holdings in shares of IQVIA by 2.7% during the fourth quarter. Nichols & Pratt Advisers LLP MA now owns 109,144 shares of the medical research company's stock valued at $21,448,000 after buying an additional 2,899 shares during the last quarter. Metis Global Partners LLC increased its position in shares of IQVIA by 19.5% during the fourth quarter. Metis Global Partners LLC now owns 10,023 shares of the medical research company's stock worth $1,970,000 after acquiring an additional 1,633 shares in the last quarter. Finally, Fisher Asset Management LLC raised its holdings in shares of IQVIA by 112.2% in the 4th quarter. Fisher Asset Management LLC now owns 15,696 shares of the medical research company's stock worth $3,085,000 after acquiring an additional 8,298 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

NYSE IQV traded up $2.47 on Wednesday, reaching $186.04. 1,046,821 shares of the company's stock traded hands, compared to its average volume of 1,206,530. The stock has a market cap of $32.76 billion, a PE ratio of 24.81, a P/E/G ratio of 1.99 and a beta of 1.48. The stock has a 50-day simple moving average of $198.52 and a 200 day simple moving average of $213.86. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on IQV shares. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Bank of America cut their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Stephens began coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Finally, Citigroup reduced their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.